Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Metastasis02:30

Metastasis

6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors.

Digestive diseases (Basel, Switzerland)·2002
Same author

Kidney function and glomerulopathy over 8 years in young patients with Type I (insulin-dependent) diabetes mellitus and microalbuminuria.

Diabetologia·2002
Same author

Massive steatosis hepatis: an unusual manifestation of Whipple's disease.

The American journal of gastroenterology·2002
Same author

Naftidrofuryl in the treatment of vascular dementia.

European archives of psychiatry and clinical neuroscience·2002
Same author

Influence of nonylphenol on the microbial community of lake sediments in microcosms.

The Science of the total environment·2002
Same author

[Diagnosis of pancreas tumors: MRI or multidetector spiral CT?].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2002

Related Experiment Video

Updated: Mar 9, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.6K

[c-MET Oncogene in Renal Cell Carcinomas].

F Erlmeier1, W Weichert1, M Autenrieth2

  • 1Institut für Pathologie, Technische Universität München.

Aktuelle Urologie
|December 23, 2016
PubMed
Summary

The c-Met tyrosine kinase is a prognostic marker in some renal cell carcinomas and a potential target for personalized medicine. Its role in other renal tumor subtypes requires further investigation.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.6K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • c-Met, a proto-oncogene-encoded tyrosine kinase, influences cellular processes like tumor invasiveness and metastasis.
  • c-Met expression is linked to clinical outcomes and prognosis in certain renal cell carcinoma (RCC) subtypes, establishing it as a prognostic marker.
  • The precise role of c-Met across all RCC subtypes remains incompletely understood.

Purpose of the Study:

  • To explore the prognostic significance of c-Met in renal cell carcinoma.
  • To investigate the potential of c-Met as a therapeutic target in personalized medicine for RCC.
  • To clarify the role of c-Met in renal tumor subtypes where its relevance is yet to be determined.

Main Methods:

  • Literature review and analysis of existing studies on c-Met expression in renal cell carcinoma.
  • Examination of c-Met's role in tumor behavior, including invasiveness and metastasis.
  • Evaluation of c-Met's potential in targeted therapy, particularly dual inhibition of VEGF and c-MET.

Main Results:

  • c-Met is confirmed as a prognostic marker in specific subtypes of renal cell carcinoma.
  • Dual inhibition of VEGF and c-MET tyrosine kinase shows increasing clinical relevance for metastatic, treatment-resistant RCC.
  • The function and prognostic value of c-Met in other renal tumor subtypes are not yet fully elucidated.

Conclusions:

  • c-Met is a significant prognostic marker for certain renal cell carcinomas.
  • Targeting c-Met, especially in combination with VEGF inhibition, is a promising strategy for advanced, refractory RCC.
  • Further research is needed to fully understand c-Met's role in all subtypes of renal cell carcinoma and other renal tumors.